Postpartum depression affects many new mothers, but there’s new hope. The FDA has approved a medication called Zurzuveet designed to help treat postpartum depression by rebalancing brain chemicals that regulate mood.
In this video, we explain what postpartum depression is, how Zurzuveet works, and what clinical trials revealed about its effectiveness.
Alzheimer’s disease is a leading cause of dementia worldwide, but new research offers hope. Scientists at the Okinawa Institute of Science and Technology have developed a synthetic peptide, PHDP5, that shows promise in restoring neuron communication and reversing Alzheimer’s symptoms in mice.
While not a cure, this breakthrough could help slow cognitive decline and lead to improved therapies for Alzheimer’s patients.
Subscribe to ScienceMyHealth for more science-based health updates.
There’s new hope for patients with aggressive triple-negative breast cancer. Recent research shows that combining chemotherapy with the immunotherapy drug pembrolizumab before and after surgery can significantly improve survival rates.
This breakthrough treatment, highlighted in the KEYNOTE-522 trial and published in the New England Journal of Medicine, could change how this challenging cancer is treated.
Living with rheumatoid arthritis can be challenging, especially with the high cost of biologic treatments. New research from the University of Manchester shows that biosimilars—lower-cost alternatives to biologic drugs—are just as safe and effective for managing RA.
This breakthrough could make life-changing treatments more affordable and accessible to more patients.
A recent study compared magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) for major depressive disorder. Both treatments were effective in reducing depression symptoms, but MST showed advantages in memory, thinking, and faster recovery after treatment.
Published in Translational Psychiatry (2021), this research offers new insights for patients and doctors considering depression treatment options.
A new study shows that inflammation, measured by high-sensitivity C-reactive protein (CRP), may be a stronger predictor of heart attacks and cardiovascular events than LDL cholesterol levels—even in people already taking statins.
The findings suggest that monitoring and managing inflammation could play a key role in improving heart health and reducing risks for those on cholesterol-lowering medications.